My thought too...sometimes it's better action too...I just add dips heavier:
In addition, a phase 3 trial evaluating the safety and efficacy of Egalet-002 in patients with moderate-to-severe chronic pain is expected to be completed by year end.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.